Applemh1928
2021-12-08
[Miser]
[Miser]
Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":602305176,"tweetId":"602305176","gmtCreate":1638967612669,"gmtModify":1638967612800,"author":{"id":4089370506564720,"idStr":"4089370506564720","authorId":4089370506564720,"authorIdStr":"4089370506564720","name":"Applemh1928","avatar":"https://static.tigerbbs.com/3b67986ce8802c4167afe02def3d8349","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p><span>[Miser] </span><span>[Miser] </span></p></body></html>","htmlText":"<html><head></head><body><p><span>[Miser] </span><span>[Miser] </span></p></body></html>","text":"[Miser] [Miser]","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/602305176","repostId":1177589023,"repostType":2,"repost":{"id":"1177589023","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohunote.com/m/news/1177589023?lang=zh_CN&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.</p><p><blockquote>辉瑞和 biontech 股票在提供有关奥密克戎变种的最新信息后，在盘前交易中缩小了跌幅。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul> <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li> <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li> <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li> <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li> </ul> Pfizer Inc. and BioNTech SE today announced results from an initial <i>laboratory</i> study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p><p><blockquote><ul><li><i>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和奥密克戎变异株（B.1.1.529谱系），而两剂显示出中和滴度显著降低</i></li><li><i>数据表明，与针对奥密克戎变体的两个剂量相比，第三剂量的BNT162b2将中和抗体滴度增加25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，这与高水平的保护相关</i></li><li><i>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变体中突变的影响，两个剂量仍然可以诱导对严重疾病的保护</i></li><li><i>两家公司将继续推进针对奥密克戎病毒的变种特异性疫苗的开发，如果需要进行调整以进一步提高保护水平和持续时间，预计将于 3 月份上市--预计两家公司 2022 年 40 亿剂疫苗的产能不会发生变化。</i></li></ul>辉瑞公司和 BioNTech SE 今天公布了初步结果<i>实验室</i>研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在接种三剂后中和新型冠状病毒奥密克戎变体。在接受加强疫苗接种（第三剂BNT162b2疫苗）一个月后从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后野生型新型冠状病毒刺突蛋白相当。</blockquote></p><p> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p><p><blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清确实显示，与野生型相比，针对奥密克戎变体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防感染奥密克戎变体。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎突变的影响，这些公司认为，接种疫苗的个体仍然可以免受严重形式的疾病的侵害，并正在密切监测全球范围内针对奥密克戎的现实效果。</blockquote></p><p> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p><p><blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和 BioNTech 当前 COVID-19 疫苗的加强剂可将抗体滴度提高 25 倍。根据两家公司的初步数据，第三剂疫苗对奥密克戎病毒的中和抗体水平与对野生型病毒和奥密克戎病毒之前出现的其他变种疫苗接种两剂疫苗后观察到的水平相似。这些抗体水平与针对野生型病毒和这些变体的高功效相关。第三剂还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，这些刺突蛋白表位被认为与对严重疾病的保护相关。与野生型病毒相比，这些表位的绝大多数在奥密克戎刺突变体中保持不变。</blockquote></p><p> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said <b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p><p><blockquote>“虽然接种两剂疫苗仍能预防奥密克戎毒株引起的严重疾病，但从这些初步数据来看，接种第三剂疫苗可以提高保护能力，”他说。<b>Albert Bourla，辉瑞公司董事长兼首席执行官</b>. “确保尽可能多的人完全接种前两剂疫苗和加强针仍然是防止 COVID-19 传播的最佳行动方案”。</blockquote></p><p> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said <b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p><p><blockquote>“我们初步的第一批数据集表明，第三剂疫苗仍能提供足够的保护，预防奥密克戎变异株引起的任何严重程度的疾病。”<b>Ugur Sahin，医学博士，BioNTech 首席执行官兼联合创始人</b>. “在世界各地开展广泛的疫苗接种和加强运动可以帮助我们更好地保护各地的人们，并帮助他们度过冬季。我们将继续研发一种经过改造的疫苗，我们相信，与目前的疫苗相比，这种疫苗将有助于对奥密克戎引起的 COVID-19 疾病产生高水平的保护作用，并提供更持久的保护”。</blockquote></p><p></p><p> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p><p><blockquote>虽然这些结果是初步的，但这些公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发奥密克戎特异性新冠肺炎疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批总部位于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要的话，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、DeltaΑ/Delta混合）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快疫苗的适应过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。这两家公司此前曾宣布，他们预计将在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，这一产能预计不会改变。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞、BioNTech 表示第三剂疫苗中和了奥密克戎变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.</p><p><blockquote>辉瑞和 biontech 股票在提供有关奥密克戎变种的最新信息后，在盘前交易中缩小了跌幅。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul> <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li> <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li> <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li> <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li> </ul> Pfizer Inc. and BioNTech SE today announced results from an initial <i>laboratory</i> study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p><p><blockquote><ul><li><i>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和奥密克戎变异株（B.1.1.529谱系），而两剂显示出中和滴度显著降低</i></li><li><i>数据表明，与针对奥密克戎变体的两个剂量相比，第三剂量的BNT162b2将中和抗体滴度增加25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，这与高水平的保护相关</i></li><li><i>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变体中突变的影响，两个剂量仍然可以诱导对严重疾病的保护</i></li><li><i>两家公司将继续推进针对奥密克戎病毒的变种特异性疫苗的开发，如果需要进行调整以进一步提高保护水平和持续时间，预计将于 3 月份上市--预计两家公司 2022 年 40 亿剂疫苗的产能不会发生变化。</i></li></ul>辉瑞公司和 BioNTech SE 今天公布了初步结果<i>实验室</i>研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在接种三剂后中和新型冠状病毒奥密克戎变体。在接受加强疫苗接种（第三剂BNT162b2疫苗）一个月后从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后野生型新型冠状病毒刺突蛋白相当。</blockquote></p><p> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p><p><blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清确实显示，与野生型相比，针对奥密克戎变体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防感染奥密克戎变体。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎突变的影响，这些公司认为，接种疫苗的个体仍然可以免受严重形式的疾病的侵害，并正在密切监测全球范围内针对奥密克戎的现实效果。</blockquote></p><p> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p><p><blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和 BioNTech 当前 COVID-19 疫苗的加强剂可将抗体滴度提高 25 倍。根据两家公司的初步数据，第三剂疫苗对奥密克戎病毒的中和抗体水平与对野生型病毒和奥密克戎病毒之前出现的其他变种疫苗接种两剂疫苗后观察到的水平相似。这些抗体水平与针对野生型病毒和这些变体的高功效相关。第三剂还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，这些刺突蛋白表位被认为与对严重疾病的保护相关。与野生型病毒相比，这些表位的绝大多数在奥密克戎刺突变体中保持不变。</blockquote></p><p> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said <b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p><p><blockquote>“虽然接种两剂疫苗仍能预防奥密克戎毒株引起的严重疾病，但从这些初步数据来看，接种第三剂疫苗可以提高保护能力，”他说。<b>Albert Bourla，辉瑞公司董事长兼首席执行官</b>. “确保尽可能多的人完全接种前两剂疫苗和加强针仍然是防止 COVID-19 传播的最佳行动方案”。</blockquote></p><p> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said <b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p><p><blockquote>“我们初步的第一批数据集表明，第三剂疫苗仍能提供足够的保护，预防奥密克戎变异株引起的任何严重程度的疾病。”<b>Ugur Sahin，医学博士，BioNTech 首席执行官兼联合创始人</b>. “在世界各地开展广泛的疫苗接种和加强运动可以帮助我们更好地保护各地的人们，并帮助他们度过冬季。我们将继续研发一种经过改造的疫苗，我们相信，与目前的疫苗相比，这种疫苗将有助于对奥密克戎引起的 COVID-19 疾病产生高水平的保护作用，并提供更持久的保护”。</blockquote></p><p></p><p> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p><p><blockquote>虽然这些结果是初步的，但这些公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发奥密克戎特异性新冠肺炎疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批总部位于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要的话，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、DeltaΑ/Delta混合）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快疫苗的适应过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。这两家公司此前曾宣布，他们预计将在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，这一产能预计不会改变。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2893,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/602305176"}
精彩评论